Pet Drug Reports

Drugs by active ingredient

Drug · single active ingredient

Levamisole: adverse event reports

All products with this active ingredient · 2 FDA-approved applications in the Green Book

165reports naming this ingredient, 1987–20250% of all reports · about 4 a year
1reports, 12 months to March 20262 in the 12 months before
55.6%classed serious, as reportedof 9 reports stating it
38.2%record death or euthanasia, as reported63 reports
78.8%of reports concern cattle0.4% of all cattle reports

Between June 1987 and July 2025 FDA received 165 adverse event reports listing a drug with levamisole as the recorded active ingredient. The Green Book lists 2 FDA-approved applications with this single active ingredient.

openFDA masks the brand and manufacturer in every report, so these figures describe the ingredient across all products and cannot be attributed to a brand.

In the 12 months to March 2026, 1 report named it, down 50% from 2 in the 12 months before. FDA posts reports quarterly with a delay of three to six months, so the newest months are incomplete and usually grow in later releases. Over its whole reporting history that is about 4 reports a year and 0% of all 1,357,245 reports (0.4% of all cattle reports). How many animals received it is not published, so a count says nothing about how often a problem occurs per dose.

Reporters most often listed death (29.1%), alopecia NOS (13.9%) and scale (12.7%). A report can list several signs, so shares add to more than 100%; 156 different terms appear across these reports.

78.8% of reports concern cattle. Of reports that state seriousness, 55.6% were classed as serious, and 38.2% of all reports record a death or euthanasia as an outcome, as reported. FDA has not necessarily determined whether any drug played a part.

Monthly reports by species, five years

Dog1 · peak 1
Jul 2025: 12022202320242025
Cat1 · peak 1
Mar 2023: 12022202320242025
Horse0 · peak 1
2022202320242025
Other4 · peak 2
Mar 2023: 1Feb 2024: 1Aug 2024: 22022202320242025

Reports by the month FDA received them. Each panel has its own scale; the peak month is printed at the top right. The newest months are incomplete because FDA posts reports with a delay of three to six months.

Reports by year received

024471987: 1119871988: 471989: 2219891990: 141991: 819911992: 91993: 319931994: 51995: 719951996: 71997: 619971998: 12000: 220002002: 12012: 120122014: 12015: 520152016: 32017: 520172019: 12023: 220232024: 32025: 12025

2025 covers reports received through March 2026 only.

Signs listed in reports

share of levamisole reports listing the termall cattle reports

  1. Death29.1%48
  2. Alopecia NOS[hair loss, type not specified]13.9%23
  3. Scale12.7%21
  4. Hypersalivation[drooling]9.1%15
  5. Dermatitis[inflamed skin]8.5%14
  6. Recumbency[lying down and unable or unwilling to rise]6.1%10
  7. Diarrhoea[diarrhea]4.8%8
  8. Lack of efficacy - NOS[the product did not have the expected effect]4.8%8
  9. Skin lesion NOS[NOS: not otherwise specified]4.8%8
  10. Anorexia[not eating]4.2%7
  11. Ataxia[unsteady, uncoordinated movement]3.6%6
  12. Ineffective, worms NOS[legacy FDA term: the product did not have the expected effect (worms nos)]3.6%6
  13. Death by euthanasia[the animal was euthanized]3%5
  14. Unclassifiable adverse event[event that fits no dictionary term]3%5
  15. Depression[dull, quiet or withdrawn]2.4%4
  16. Overdose[more than the labelled amount was given]2.4%4
  17. PR-lung(s), lesion(s)[legacy FDA term: lesions found in the lungs]2.4%4
  18. Behavioural disorder NOS[behaviour change, type not specified]1.8%3
  19. Neurological symptoms NOS[NOS: not otherwise specified]1.8%3

Top 30 of 156 coded terms (VeDDRA, the veterinary reporting dictionary; plain-language gloss in brackets). One report can list several terms. The ticks show how often the same term appears in a wider pool of reports; they describe the reports, and FDA cautions that such figures cannot be used to estimate risk or to compare one product with another. openFDA masks brand and manufacturer names in adverse event records, so the reports counted here cannot be attributed to a particular brand.

Outcomes and report types

Outcome recorded in the report

Recovered/Normal1.8%3
Recovered with Sequela0%0
Ongoing1.2%2
Died37%61
Euthanized1.2%2
Outcome Unknown3%5

What kind of report it was

Safety issue97%160
Lack of expected effectiveness0.6%1
Both safety and lack of expected effectiveness1.2%2
Manufacturing or product defect1.2%2
Other0%0

Coloured bar: reports naming levamisole. Grey bar: all 1,357,245 reports in the database. Outcomes are the status at the time of the last report, as stated by the reporter; a report covering several animals can carry more than one outcome. FDA has not necessarily determined whether any drug played a part in any outcome.

Species and breeds in the reports

Species

Cattle78.8%130
Human exposure8.5%14
Sheep5.5%9
Goat2.4%4
Dog1.2%2
Horse1.2%2

Single-breed animals

Breed shares follow how common each breed is. Crossbred animals and reports with no breed stay in the species figure only.

Age, weight and route

Age of the animal

Under 1 year12.7%21
1 to 3 years20%33
4 to 7 years7.9%13
8 to 11 years2.4%4
12 years and over3.6%6
Age not given53.3%88

Weight of the animal

Under 5 kg (11 lb)0.6%1
5 to 9.9 kg (11–22 lb)1.8%3
10 to 24.9 kg (22–55 lb)3%5
25 to 44.9 kg (55–99 lb)0%0
45 kg and over (99 lb+)53.3%88
Weight not given41.2%68

Route of administration stated in reports: topical (142), oral (11).

In context

MeasureLevamisoleAll cattle reportsAll reports
Reports16531,2291,357,245
Share of that pool's reports naming this drug—0.4%0%
Classed serious, of reports stating it55.6%58.4%38.6%
Death or euthanasia recorded, per 1,000 reports381.836863.8
Filed as lack of expected effectiveness (wholly or partly)1.8%—23%
Top term, share of reportsDeath 29.1%29.4%—

This set accounts for 94.3% of all reports naming levamisole, so no separate ingredient column is shown. Shares are of reports, not of animals treated. The number of doses sold is not public, so none of these figures is a rate of occurrence, and differences between columns reflect which animals receive a drug and who reports as much as anything else.

FDA-approved products containing levamisole (Green Book)

Reference information, not report statistics. openFDA masks brand and manufacturer names in adverse event records, so the reports counted here cannot be attributed to a particular brand. The list below is the FDA Green Book as of 1 Oct 2026; nothing on this page says which of these products, if any, a report concerned.

Trade nameActive ingredientsSponsorApproved forApplication
Totalon Topical Cattle AnthelminticLevamisoleIntervet, Inc.CattleNADA 139-877
Tramisol Pour-OnLevamisoleZoetis Inc.CattleNADA 140-844

Species are the major species the Green Book search lists for the application ("—" where it lists another species or none). Approval dates are not part of the Green Book listing files and are not shown. Pioneer applications (NADA) come first, then generics (ANADA).

Questions about levamisole reports

How many adverse event reports has FDA received for levamisole?

165 reports record a drug with levamisole as its active ingredient in the openFDA release of 28 Sep 2026, covering reports received through March 2026. 1 of them arrived in the latest 12 months.

Which brand do these reports concern?

That cannot be known from the public data. openFDA masks brand and manufacturer names in adverse event records, so the reports counted here cannot be attributed to a particular brand. The Green Book lists 2 approved applications with this ingredient alone; the reference list on this page names them without any counts.

What signs are reported most often?

death (29.1%), alopecia NOS (13.9%), scale (12.7%), hypersalivation (9.1%) and dermatitis (8.5%). These are the coded terms listed in reports; several can appear in one report, and a term's presence is not a finding that the drug was responsible.

Which species and breeds appear in these reports?

cattle (78.8%), human exposure (8.5%) and sheep (5.5%). Among single-breed animals the most frequent labels are Hereford cattle, Limousin, Brahman and Charolais; popular breeds appear often in any drug's reports because there are more of them.

Are reports rising?

1 reports in the 12 months to March 2026, down 50% from 2 in the 12 months before. FDA posts reports quarterly with a delay of three to six months, so the newest months are incomplete and usually grow in later releases. Counts also move with sales, publicity and time on the market.

Do these reports show that levamisole harms pets?

Report counts cannot show that. FDA states that "there is no certainty that the reported drug or device caused the adverse event" and that the event "may have been related to an underlying disease, other drugs used at the same time or other non-drug related sources." FDA also notes that commonly used products may have more reports simply because more animals receive them.

Are these the side effects of levamisole?

They are signs listed in reports, not an established list of side effects. The adverse reactions observed in studies are printed on each product's FDA-approved label, which a veterinarian can go through with you. This page is a record of what was reported to FDA.

How do I report a problem with an animal drug?

FDA asks owners and veterinarians to call the drug company first (the number is on the label); companies must pass reports to FDA. Reports can also go directly to FDA on Form FDA 1932a. See the guide on how to report.

Where this comes from. Counts are built from the openFDA Animal & Veterinary adverse event bulk files released 28 Sep 2026, which hold reports FDA's Center for Veterinary Medicine received through 31 Mar 2026. openFDA masks brand and manufacturer names in these files, so drugs are counted by the active ingredients each record discloses and no figure is attributed to a brand, application or company. Ingredient names, and the separate reference lists of approved products, follow the FDA Green Book as of 1 Oct 2026. Drug entries are grouped by the active ingredients their unmasked ingredient field discloses; the application number that records also carry is not used. No report text, lot numbers or reporter details are published. See the methodology and sources; FDA's record is authoritative, and corrections are handled within five working days.